Inhibitors of the interaction between P53 and MDM2

Details Inhibitors of the interaction between P53 and MDM2 Inhibitors of the interaction between P53 and MDM2

2006-08-01

2006-08-01

Zara, Jane (Department: 1635)

Chemistry: analytical and immunological testing

Biospecific ligand binding assay

C424S001410, C424S001690, C435S007100, C530S300000, C530S317000, C530S328000

Reexamination Certificate

active

07083983

ABSTRACT:
The present invention relates to compounds capable of binding to the oncogene protein MDM2, processes for the preparation of such compounds, pharmaceutical preparations comprising such compounds, and uses of said compounds, e.g. in the therapeutic (including prophylactic) treatment of an animal or especially of the human body. The present further relates to methods of and compounds for inhibiting the growth of tumor cells which comprise the wild type p53 suppressor by interfering with the interaction between human p53 and human MDM2.

REFERENCES:
patent: 5362623 (1994-11-01), Vogelstein et al.
patent: 5411860 (1995-05-01), Vogelstein et al.
patent: 5420263 (1995-05-01), Burrell et al.
patent: 5519118 (1996-05-01), Vogelstein et al.
patent: 5532348 (1996-07-01), Huibregtse et al.
patent: 5550023 (1996-08-01), Kinzler et al.
patent: 5606044 (1997-02-01), Burrell et al.
patent: 5618921 (1997-04-01), Burrell et al.
patent: 5702908 (1997-12-01), Picksley et al.
patent: 5770377 (1998-06-01), Picksley et al.
patent: 6051384 (2000-04-01), Zentgraf et al.
patent: 6121238 (2000-09-01), Dower et al.
patent: 6153391 (2000-11-01), Picksley et al.
patent: WO 93 20238 (1993-10-01), None
patent: WO 94/00601 (1994-01-01), None
patent: WO 95 07934 (1995-03-01), None
patent: WO 96 02642 (1996-02-01), None
patent: WO 98/01467 (1998-01-01), None
patent: WO 98/13064 (1998-04-01), None
Report and recommendations of the pane to assess the NIH investment in research on gene therapy. Orkin and Motulsky, co chairs. National Institutes of Health (Dec. 1995).
Crystal, R. G. Transfer of genes to humans: Early lessons and obstacles to success. Science 270: 404-410 (Oct. 1995).
Rojanasakul, Y. Antisense oligonucleotide therapeutics: Drug deliver and targeting. Adv. Drug Delivery Rev. 18: 115-131 (1996).
Stull et al. Antigene, ribozyme and aptamer nucleic acid drugs: Progress and prospects. Pharm. Res. 12:465-483 (Apr. 1995).
Parsons, J.A., Ed. Peptide Hormones. Univ. Park Press, Baltimore (1976).
Lee, H. et al. Gene vol. 184: 177-183 (1997).
Bottger, V. et al., Oncogene, vol. 13, pp. 2141-2147 (1996).
Elliott,G. et al., Cell, vol. 88, pp. 223-233 (1997).
Derossi, D. et al., J. Biol. Chem., vol. 289, No. 14, pp. 10,444-10,450 (1994).
Pooga, M. et al., FASEB J., vol. 12, pp. 67-77 (1998).
Ball K. et al., Current Biology, vol. 7 (1), “Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1,” pp. 71-80 (1996).
Blaydes J. et al., Oncogene, vol. 14, “Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2,” pp. 1859-1868 (1997).
Blommers M.J.J. et al., J. Am. Chem. Soc., vol. 119 (14), “On the Interaction Between p53 and MDM2: Transfer NOE Study of a p53-Derived Peptide Ligated to MDM2,” pp. 3425-3426 (1997).
Böttger A. et al., J. Mol. Biol., vol. 269, “Molecular Characterization of the hdm2-p53 Interaction,” pp. 744-756 (1997).
Böttger V. et al., Oncogene, vol. 18, “Comparative study of the p53-mdm2 and p53-MDMX interfaces,” pp. 189-199 (1999).
Böttger V. et al., Oncogene, vol. 13, “Identification of novel mdm2 binding peptides by phage display,” pp. 2141-2147 (1996).
Chorev M. and Goodman M., Acc. Chem. Res., vol. 26, “A Dozen Years of Retro-Inverso Peptidomimetics,” pp. 266-273 (1993).
Derossi D. et al., J. of Biol. Chem., vol. 269 (14), “The Third Helix of the Antennapedia Homeodomain Translocates through Biological Membranes,” pp. 10444-10450 (1994).
Gannon J. et al., Oncogene, vol. 9 (5), “Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form,” pp. 1595-1602 (1990).
Lane D., Exp. Opin. Ther. Patents, vol. 6 (8), “Patent Evaluation—Oncologic, Endocrine & Metabolic—Interruption of binding of MDM-2 and p53 protein; potential for the treatment of cancer,” pp. 805-809 (1996).
Lee H. et al., J. Bacteriol., vol. 173 (17), “Molecular Characterization of nosA, aPseudomonas stutzeriGene Encoding an Outer Membrane Protein Required to Make Copper-Containing N20 Reductase,” pp. 5406-5413 (1991).
Lin J. et al., Genes & Devel., vol. 8 (10), “Several hydrophobic amino acids in the p52 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein,” pp. 1235-1246 (1994).
Lin Y-Z et al., J. of Biol. Chem., vol. 270 (24), “Inhibition of Nuclear Translocation of Transcription Factor NF-κB by a Synthetic Peptide Containing a Cell Membrane-permeable Motif and Nuclear Localization Sequence,” pp. 14255-14258 (1995).
Momand J. et al., Cell, vol. 69, “The mdm-2 Oncogene Product Forms a Complex with the p53 Protein and Inhibits p53-Mediated Transactivation,” pp. 1237-1245 (1992).
Mundt M. et al., “The tumor suppressor p53 as a target for tumor therapy: AnIn vitrotranscription system as an indicator of active p53,” Abstract of presentation at University of Dundee, Dundee, Scotland, Jul. 5-9, 1996.
Olson D. et al., Oncogene, vol. 8, “Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes,” pp. 2353-2360 (1993).
Phelan J.C. et al., J. of Amer. Chem. Soc., vol. 119 (3), “A General Method for Constraining Short Peptides to an α-Helical Conformation,” pp. 455-460 (1997).
Picksley S. et al., Oncogene, vol. 9, “Immunochemical analysis of the interaction of p53 with MDM2;—fine mapping of the MDM2 binding site on p53 using synthetic peptides,” pp. 2523-2529 (1994).
Picksley S. and Lane D., Current Opinion in Cell Biology, vol. 6, “p53 and Rb: their cellular roles,” pp. 853-858 (1994).
Wallace C. Current Opinion in Biotechnology, vol. 6, “Peptide ligation and semisynthesis,” pp. 403-410 (1995).
Barak, Y. et al., “mdm2 expression is inducted by wild type p53 activity,” EMBO J., 12(2): 461-468, Feb. 1993.
Barak Y & Oren M., “Enhanced binding of a 95 kDa protein to p53 in cells undergoing p-53- mediated growth arrest,” EMBO J., 11(6):2115-2121, Jun. 1992.
Böttger A. et al., “Design of a synthetic Mdm2-binding mini protein that activates the p53 responsein vivo,” Curr. Biol. 7:860-869, Oct. 1997.
Brown D.R. et al., “The tumor suppressor p53 and the oncoprotein simian virus 4D T antigen bind to overlapping domains on the MDM2 protein,” Mol. Cell. Biol., 13(11): 6849-6857, Nov. 1993.
Cahilly-Snyder L. et al., “Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line,” Somatic Cell Mol: Genet., 13 (3): 235-244, May 1987.
Chen C.Y. et al., “Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway,” PNAS USA, 91(7): 2684-2688, Mar. 1994.
Chen J. et al., “Mapping of the p53 and mdm-2 interaction domains,” Mol. Cell Biol., 13: 4107-4114, Jul. 1993.
Colas P. et al., “Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2,” Nature, 380: 548-550, Apr. 1996.
Deffie A. et al., “The tumor suppressor p53 regulates its own transcription,” Mol. Cell. Biol., 13: 3415-3423, Jun. 1993.
Dyson N. et al., “Adenovirus E1A makes two distinct contacts with the retinoblastoma protein,” J. Virology, 66; 4606-4611, Jul. 1992.
Dyson N. et al., “Homologus sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins,” J. Virology, 66: 6893-6902, Dec. 1992.
Farmer G. et al., “Wild-type p53 activates transcriptionin vitro,” Nature, 358: 83-86, Jul. 1992.
Finlay, C.A., “The mdm-2 Oncogene can overcome wild-type p53 suppression of transformed cell growth,” Mol. Cell. Biol., 13(1): 301-306, Jan. 1993.
Florenes V.A. et

Affiliated with

Also associated with

Rating

Inhibitors of the interaction between P53 and MDM2 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of the interaction between P53 and MDM2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of the interaction between P53 and MDM2 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3656797